Papillomavirus Vaccines - Administration & dosage
Research News and Information

Monday, November 23, 2009

EUROGIN 2008 roadmap on cervical cancer prevention.

13 Nov 2009 The EUROGIN 2008 Roadmap represents a continuing effort to provide updated information on primary and secondary prevention of cervical cancer. The report addresses several areas including the progress made toward global implementation of currently ... Read more...

Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization.

29 Sep 2009 OBJECTIVE: To examine the rate and correlates of completion of the quadrivalent human papillomavirus vaccine (HPV4) 3-dose regimen because nonadherence to the regimen may adversely affect vaccine efficacy. PARTICIPANTS AND METHODS: Female members of ... Read more...

[Basaloid squamous cell carcinomas of the head and neck]

29 Sep 2009 Basaloid squamous cell carcinomas (SCC) are a rare variant of SCC of the head and neck. Their histological characteristics have been described by Wain in 1986 and are reported in the 2005 WHO classification. A poorer prognosis of BSCC has been ... Read more...

Latest indexed articles for 'Papillomavirus Vaccines - Administration & dosage'

These are the very latest articles for this heading:

• EUROGIN 2008 roadmap on cervical cancer prevention. 13 Nov 2009
• Taking the service to the young people: a study and analysis of a clinic specifically set up for HPV vaccination provision. 29 Sep 2009
• Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. 29 Sep 2009
• [Basaloid squamous cell carcinomas of the head and neck] 29 Sep 2009
• Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. 29 Sep 2009
• Natural history of HPV infections. 30 Aug 2009
• Integrating HPV vaccination into your practice: overcoming common barriers. 30 Aug 2009
• What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. 16 Aug 2009
• The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. 16 Aug 2009
• Estimating coverage of the National HPV Vaccination Program: where are we at? Aug 2009
• Update: Vaccines for women, adolescence through adulthood. 30 Jul 2009
• Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. 30 Jul 2009
• Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. 30 Jul 2009
• A qualitative study to assess school nurses' views on vaccinating 12-13 year old school girls against human papillomavirus without parental consent. 19 Jul 2009
• Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. 17 Jul 2009
• Implementation of the Australian HPV vaccination program for adult women: qualitative key informant interviews. 16 Jul 2009
• [Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization] 29 Jun 2009
• Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. 29 Jun 2009
• Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. 29 Jun 2009
• How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. 26 Jun 2009

See a longer list of these articles.

Technical information about 'Papillomavirus Vaccines'

Definition: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.

Registry Number: 0

Descriptor UI: D053918

Alternative terms: Papillomavirus Vaccines; Vaccines, Papillomavirus; Human Papillomavirus Vaccines; Papillomavirus Vaccines, Human; Vaccines, Human Papillomavirus; Human Papilloma Virus Vaccines; HPV Vaccines;

Related Mesh Headings: Cancer Vaccines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D20.215.894.899.498;

History Note: 2007